ABSTRACT
Objective To investigate the effect of nutritional guidance on the energy intake and body weight of patients with gastric cancer chemotherapy. Methods The experimental study was used to study the 144 cases with gastric cancer for the first time of chemotherapy. They were randomly divided into the experimental group and the control group, 72 cases in each group. Routine healthy guidance was used in the control group, while the patients in the experimental group were treated by the nutrition prescription, the nutrition guidance, the purpose and the significance of the chemotherapy, and the follow-up of the patients after discharge. The body weight of patients was collected before chemotherapy, and the dietary questionnaire was used for second days after first days of dietary intake, and the changes of energy consumption and body weight were compared between the two groups. Results The mean values of energy intake within 24 hours in the first 3 days after the chemotherapy in the experimental group was 5 068.92 kJ, which was 51%of the RNI. The mean values of energy intake within 24 hours in the first 3 days after the chemotherapy in the control group was 3 439.25 kJ, which was 38%of the RNI. The difference between the two groups was significant (P<0.01). The weight of patients in the experimental group at the time point of before the 5th and 6th time of chemotherapy were significant higher than those in the control group (P<0.05). Energy intake had influenced the patients′weight, high energy intake with low decrease of body weight. Conclusions Nutritional guidance can effectively improve the energy intake of patients with gastric cancer when chemotherapy, so that the weight remained stable during chemotherapy.
ABSTRACT
Objective To explore the effect of nursing instruction on the compliance of patients with gastric cancer after chemotherapy. Methods Selected 144 patients who had underwent surgey for gastric cancer after the first chemotherapy from May 2013 to December 2014. Randomly divided into experimental group and control group, Health education for patients in the control group during the period of hospitalization and before discharge. Follow up the implementation of the first chemotherapy after the first follow-up nursing guidance. Patients in the experimental group on the basis of the implementation of the whole process of continuing nursing guidance, including the increase in the duration of hospitalization, nutrition education, nutrition, prescription and adverse drug reaction to respond to chemotherapy. After each chemotherapy, the telephone follow-up was carried out to guide the treatment of nutritional intake and adverse effects of chemotherapy, emphasizing the importance of chemotherapy. The chemotherapy compliance of the two groups were compared. Results The median number of chemotherapy in the experimental group was 6, while that was 4.5 in the control group, the difference was statistically significant, Z=2.672, P=0.008. The adverse reaction was the main reason for the loss of patients with chemotherapy, the drop rate in the control group because of adverse reaction of chemotherapy was higher than that of in the experimental group, χ2=3.973, P=0.046, the difference was statistically significant. Conclusions Due to serious adverse reactions in patients with gastric cancer after operation, chemotherapy confidence needs to be strengthened. The whole process of continuous nursing guidance is conducive to the patient′s chemotherapy confidence, improve the patient's chemotherapy compliance.
ABSTRACT
Background: vascular access ports (VAPs) are designed to allow repeated access to the vascular system with minimum patient distress. Objective: to describe the surgical technique, care and complications of jugular VAPs currently used at the Veterinary Oncology Service of the University of Florida Small Animal Hospital. Conclusion: the VAPs can remain in site for long terms (months) with minimum complications, and its placement is a reliable technique that should be considered by veterinarians, particularly for a longterm treatment.
Antecedentes: los catéteres venosos centrales (VAPs) están diseñados para permitir el acceso repetido al sistema vascular con las mínimas molestias para el paciente. Objetivo: describir la técnica quirúrgica, atención de mantenimiento y las complicaciones de los VAPs en vena yugular, que se utiliza actualmente en el Veterinary Oncology Service en la University of Florida Small Animal Hospital. Conclusión: el VAP puede permanecer en el lugar durante períodos largos (meses) con pocas complicaciones, y su implantación quirúrgica debe ser considerada por los veterinarios, en particular para el tratamiento a largo plazo.
Antecedentes: os cateteres venosos centrais (VAPs) permitem acessos repetidos ao sistema vascular com mínimo desconforto ao paciente. Objetivo: descrever a técnica cirúrgica, cuidados de manutenção e complicações dos VAPs de veia jugular utilizados atualmente no Serviço de Oncologia Veterinária do Hospital Veterinário de Pequenos Animais da Universidade da Florida. Conclusão: o VAP pode permanecer no local por longos períodos (meses) com poucas complicações. O implante cirúrgico descrito no presente trabalho deve ser considerado pelos médicos veterinários, particularmente para tratamentos de longa duração.
ABSTRACT
Objective To evaluate the efficacy and safety of lentinan injection plus cisplatin (LIC) in the treatment of malignant pleural effusion (MPE).Methods We searched the database of Cochrane Library,PubMed,EMBASE,ISI Web of Knowledge,Chinese Biomedical Literature Database,Chinese Scientific Journals Full-text Database,Chinese Journal Full-text,and Google Scholar,etc.,up to February 28th,2011 to identify randomized controlled trials (RCTs) about lentinan injection (LI) for MPE,evaluate the quality of the included studies,and analyze the data by Cochrane Collaboration's RevMan5.0 software.Results Twenty-nine RCTs involving 1831 patients were included.Meta analysis results suggested that there were some differences when comparing LIC with control groups suffering from MPE,for LIC could improve the near-term curative effect and the quality of life to some extent.Besides,compared with chemotherapy alone,LI plus chemotherapy had an advantage in relieving adverse reactions,such as gastrointestinal reactions,myelosuppression,chest pain,and general malaise.Conclusion The current evidence indicates that LI may have adjuvant therapeutic effects for MPE.
ABSTRACT
Objective: To evaluate the clinical efficacy and adverse events of high dose of ifosfamide (IFO) in combination with cisplatin (DDP) in the treatment of advanced osteosarcoma. Methods: Twenty-three patients with advanced osteosarcoma confirmed by pathological examination were enrolled in this study. All the patients were given IFO 10.0 g/m2 combined with intravenous infusion of DDP 80 mg/m2. The efficacy and adverse events of combined therapy were evaluated according to the WHO standard on the short-term curative effect and adverse reactions of anti-tumor drugs. Results: The effective rate was 64.70% (17/23) in patients with distant metastasis. The effective rate was significantly higher in 13 patients with lung metastases than that in patients with bone metastases and regional recurrence. The major adverse events of drugs were vomitting, morrow inhibition and neurotoxicity. The incidence of III-IV grade gastrointestinal reaction and gramilocytopenia was 49.32% and 30.13%, respectively. The adverse reaction was observed in nervous system simultaneously. Conclusion: The high dose of IFO combined with DDP bad definite effects on advanced osteosarcoma. The most adverse effects were well tolerated. Therefore, it could become an adjuvant chemotherapy for osteosarcoma.
ABSTRACT
0.05). WHO grade Ⅲ/Ⅳ neutropenia 10%in BL groups,47% in BCNU groups.The BL groups was longer than BCNU groups in survival time(P
ABSTRACT
Background and purpose:Paclitaxel and cisplatin were demonstrated to be effective and well-tolerated for advanced gastric cancer.The clinical efficacy of hyperthermic intraperitoneal perfusion(CHPP) has been established in numerous studies in recent years.The purpose of the study was to evaluate the efficacy and toxicities of paclitaxel combined with CHPP with cisplatin in the treatment of patients with advanced gastric cancer.Methods:51 patients with advanced gastric cancer were randomized into systemic chemotherapy group(25 patients) who received paclitaxel 70 mg/m2,iv,1/wk?8wk,DDP 25 mg/m2,iv,d1-3,reapeated every 3 weeks for 4 cycles and systematic plus CHPP group(26 patients)who received paclitaxel 70 mg/m2,iv,1/wk?8wk,DDP 60 mg/m2,CHPP,d1,8,22,29,and abdomen hyperthermia treatment twice a week in the whole chemotherapy period.Results:The response rate(CR+PR),the clinical benefitial response(CBR) in systematic plus CHPP group were 65.4% and 92.3%,and those in systemic chemotherapy group were 36.0% and 68.0%.There was obviously a statistical difference between two groups(P0.05).The major toxicities were myelo-suppression and nausea/vomiting.There was no significant difference in side-effect between the two groups.Conclusions:Paclitaxel administered by weekly infusion combined with hyperthermic intraperitoneal perfusion chemotheraphy with cisplatin in the treatment of advanced gastric cancer is effective and tolerable.It is worth studying in the future.
ABSTRACT
Purpose:To evaluate the short-term effect of combination chemotherapy of oxaliplatin plus capecitabine on advanced cancer.Methods:32 patients of advanced gastric cancer were treated with oxaliplatin plus capecitabine for 76 weeks.Results:There were 6 CR, 16 PR, 8 NC, 2 PD, in our group and the overall response rate was 68.75% (22/32). The median alleviative time was 8 months, the median survival time was 12 months and the one-year survival rate was 55%. 30(93.75%) patients benefited from this method. The side effects were all tolerable which were alleviated by active therapy. There was no death and nobody stopped chemotherapy because of side effects.Conclusions:Combination chemotherapy of oxaliplatin plus capecitabine to treat advanced gastric cancers was certainly effective and tolerable to toxicities. This chemotherapy will be used as the first-line in more patients and is worthy of further study.[
ABSTRACT
150 g/L, the dose of EPO was decreased by half. The control group consisted of 20 patients given Leucogenum, the dose was 20 mg every time, 3 times per day. Results: From the fourth week after therapy, the Hb, HCT, RBC of the EPO treatment group was significantly higher than prior to treatment( P
ABSTRACT
The expression of p-glycoprotein (p-gp) was evaluated in pre- and post-chemotherapy states after the administration of adriamycin-based chemotherapy in 24 gastric cancer patients. Among them, group A was composed of twelve patients who relapsed after surgery plus adjuvant chemotherapy and group B was composed of another twelve patients who received neoadjuvant chemotherapy plus surgery. Pre-chemotherapy p-gp was evaluated in 18 out of 24 patients (6 patients had no pre-chemotherapy paraffin blocks) and post-chemotherapy p-gp was evaluated from all 24 patients. Pre- and post-chemotherapy p-gp was expressed in 5 of 18 patients (27.8%), and 9 of 24 patients (37.5%), respectively, with immunohistochemical stain using monoclonal antibody JSB-1. No differences of disease-free survivals were observed in Group A based on post-chemotherapy p-gp expression from relapsed lesions. In Group B, there was a higher relapse rate (p = 0.04) and a lower one-year disease-free survival rate (p = 0.04) in post-chemotherapy p-gp positive patients when adjuvant treatment was done with the same regimen as neoadjuvant chemotherapy. In all patients studied, post-chemotherapy p-gp expression correlated with a higher systemic recurrence (p = 0.04). These data suggest that p-gp can be induced by an adriamycin-based chemotherapy in gastric cancer. Thus, we suggest that the prognosis of gastric cancer may be poor if a multidrug resistance (MDR)-related regimen is used in the presence of p-gp after neoadjuvant chemotherapy with an adriamycin-based regimen, even if the initial response is good.